EP 0808328 A1 19971126 - NOVEL FARNESYL TRANSFERASE INHIBITORS, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
Title (en)
NOVEL FARNESYL TRANSFERASE INHIBITORS, PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
Title (de)
INHIBITOREN DER FARNESYLTRANSFERASE, IHRE HERSTELLUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN
Title (fr)
INHIBITEURS DE FARNESYL TRANSFERASE, LEUR PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
Publication
Application
Priority
- FR 9600198 W 19960207
- FR 9501489 A 19950209
Abstract (en)
[origin: WO9624611A1] Novel farnesyl transferase inhibitors of general formula (I), preparation thereof, and pharmaceutical compositions containing same. In general formula (I), R1 is Y-S-A1- (where Y is a hydrogen atom, an amino acid residue, a fatty acid residue, an alkyl or alkoxycarbonyl radical, or a radical R4-S-, where R4 is a C1-6 alkyl radical optionally substituted by a phenyl radical, or a radical of general formula (II), wherein A1, X1, Y1, R2, R'2, X2, Y2, X, R3, R'3 and R are as defined below, and A1 is a C1-4 alkylene radical optionally alpha -substituted in the >C(X1)(Y1) grouping by an amino, alkylamino, alkanoylamino or alkoxycarbonylamino radical); X1 and Y1 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, a >C=O grouping; R2 is a straight or branched C1-4 alkyl radical optionally substituted by a cyclohexyl radical; R'2 is hydrogen or alkyl; X2 and Y2 are each a hydrogen atom or, taken together with the carbon atom to which they are attached, a >C=O grouping; R3 is a C1-4 alkyl radical optionally substituted by hydroxy, alkoxy, mercapto, alkylthio, alkylsulphinyl or alkylsulphonyl, with the proviso that, when R3 is an alkyl radical substituted by a hydroxy radical, R3 may form a lactone with the alpha -carboxy radical; R'3 is hydrogen or alkyl; X is an oxygen or sulphur atom; and R is a hydrogen atom or an optionally substituted alkyl radical or an optionally substituted phenyl radical. These novel products have anticancer properties.
IPC 1-7
IPC 8 full level
A61K 38/00 (2006.01); A61P 35/00 (2006.01); A61P 43/00 (2006.01); C07K 5/103 (2006.01)
CPC (source: EP KR US)
A61K 38/07 (2013.01 - KR); A61P 35/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 5/1005 (2013.01 - KR); C07K 5/1013 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US)
Citation (search report)
See references of WO 9624611A1
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
WO 9624611 A1 19960815; AU 4722796 A 19960827; BR 9607317 A 19971230; CA 2210955 A1 19960815; CN 1173874 A 19980218; CZ 249897 A3 19971112; EP 0808328 A1 19971126; FI 973278 A0 19970808; FI 973278 A 19970808; FR 2730491 A1 19960814; FR 2730491 B1 19970314; JP H10513467 A 19981222; KR 19980702048 A 19980715; MX 9706015 A 19971129; NO 973608 D0 19970805; NO 973608 L 19970805; PL 321675 A1 19971222; SK 108797 A3 19971210; TR 199700727 T1 19980221; US 5856439 A 19990105; ZA 961072 B 19960820
DOCDB simple family (application)
FR 9600198 W 19960207; AU 4722796 A 19960207; BR 9607317 A 19960207; CA 2210955 A 19960207; CN 96191867 A 19960207; CZ 249897 A 19960207; EP 96903061 A 19960207; FI 973278 A 19970808; FR 9501489 A 19950209; JP 52403796 A 19960207; KR 19970705443 A 19970807; MX 9706015 A 19960207; NO 973608 A 19970805; PL 32167596 A 19960207; SK 108797 A 19960207; TR 9700727 T 19960207; US 87575297 A 19970801; ZA 961072 A 19960209